José Luis
Bello López
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, EspañaPublicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (28)
2020
-
Novel Mutation Hotspots within Non-Coding Regulatory Regions of the Chronic Lymphocytic Leukemia Genome
Scientific Reports, Vol. 10, Núm. 1
2019
-
A Three-Gene Expression Signature Identifies a Cluster of Patients with Short Survival in Chronic Lymphocytic Leukemia
Journal of Oncology, Vol. 2019
-
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807
-
Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia
Blood cancer journal
-
New Recurrent Structural Aberrations in the Genome of Chronic Lymphocytic Leukemia Based on Exome-Sequencing Data
Frontiers in Genetics, Vol. 10
-
The association of germline variants with chronic lymphocytic leukemia outcome suggests the implication of novel genes and pathways in clinical evolution
BMC Cancer, Vol. 19, Núm. 1
2017
-
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
British Journal of Haematology, Vol. 178, Núm. 5, pp. 699-708
2016
-
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial
Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899
2014
-
Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy
Tumori, Vol. 100, Núm. 2, pp. 225-231
-
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?
Blood, Vol. 124, Núm. 12, pp. 1887-1893
-
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial
British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336
-
Simplification of risk stratification for splenic marginal zone lymphoma: A point-based score for practical use
Leukemia and Lymphoma
2013
-
Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)
Medical Mycology, Vol. 51, Núm. 2, pp. 150-154
-
Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment
Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952
2012
-
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Blood, Vol. 120, Núm. 13, pp. 2581-2588
-
Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases
British Journal of Haematology, Vol. 159, Núm. 2, pp. 164-171
2009
-
Anagrelide treatment in early pregnancy in a patient with JAK2V617F-positive essential thrombocythemia: Case report and literature review
Acta Haematologica, Vol. 122, Núm. 4, pp. 221-222
2007
-
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
Leukemia, Vol. 21, Núm. 1, pp. 143-150
-
Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients
Biology of Blood and Marrow Transplantation, Vol. 13, Núm. 12, pp. 1448-1454